Wells Fargo & Company Day One Biopharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 56,936 shares of DAWN stock, worth $897,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,936

Previous 45,761 24.42%

Holding current value

$897,311

Previous $755,000 3.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$12.03 - $17.69 $134,435 - $197,685	11,175 Added 24.42%	56,936 $784,000
Q1 2024 May 10, 2024	BUY	$13.56 - $17.46 $102,188 - $131,578	7,536 Added 19.71%	45,761 $755,000
Q4 2023 Feb 09, 2024	SELL	$9.68 - $15.37 $381,256 - $605,362	-39,386 Reduced 50.75%	38,225 $558,000
Q3 2023 Nov 13, 2023	SELL	$11.22 - $14.86 $149,787 - $198,381	-13,350 Reduced 14.68%	77,611 $952,000
Q2 2023 Aug 15, 2023	BUY	$11.74 - $14.47 $392,151 - $483,341	33,403 Added 58.03%	90,961 $1.09 Million
Q1 2023 May 12, 2023	BUY	$12.75 - $23.41 $469,671 - $862,354	36,837 Added 177.78%	57,558 $769,000
Q4 2022 Feb 13, 2023	SELL	$18.77 - $22.0 $4,842 - $5,676	-258 Reduced 1.23%	20,721 $445,000
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $12,609 - $20,379	767 Added 3.79%	20,979 $420,000
Q2 2022 Aug 12, 2022	BUY	$5.72 - $17.9 $58,412 - $182,794	10,212 Added 102.12%	20,212 $362,000
Q1 2022 May 16, 2022	SELL	$9.12 - $17.47 $5,946 - $11,390	-652 Reduced 6.12%	10,000 $99,000
Q4 2021 Feb 14, 2022	BUY	$15.65 - $26.33 $9,374 - $15,771	599 Added 5.96%	10,652 $180,000
Q3 2021 Nov 15, 2021	BUY	$20.0 - $27.92 $201,060 - $280,679	10,053 New	10,053 $238,000

Others Institutions Holding DAWN

# of Institutions

169

Shares Held

73.1M

Call Options Held

163K

Put Options Held

183K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $1.16B
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Day One Biopharmaceuticals, Inc. Transaction History